Biotechnology and Patent Rights: Seeking the Common Good?

  • Odelia Funke
Part of the International Political Economy Series book series (IPES)


Biological research and its commercial applications are posing fundamental and complex questions for policy-makers, from privacy rights to reproductive rights to issues of whether there is a right to die, and even what constitutes death and how to define a human being. Recombinant DNA (rDNA) presents particularly complex issues across a number of categories: risks (for research as well as distribution and disposal), including intergenerational and long-term ecological effects on both national and international levels; expenditure of public funds for R&D; patenting rights; effects on domestic economies and on the international balance of payments; and effects on academic science. Last, and perhaps most important, are the potentially profound changes to society as rDNA products enter the market — from effects on small farms to changes in reproductive choices to the introduction of wholly new kinds of evidence admissible in court.


Civil Society Life Form Patent Protection North American Free Trade Agreement Liberal Government 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    See, for example, Stephanie Chong, ‘The Relevancy of Ethical Concerns in the Patenting of Life Forms’, Canadian Intellectual Property Review, 10, 1 (September 1993): 189–207.Google Scholar
  2. 3.
    John Locke, Two Treatises of Government, Peter Laslett (ed.) (New York: New American Library, 1965), Second Treatise (II), Chap. V, §35, 21–3: 334. The Earth ‘is given to Men for the Support and Comfort of their being…and no body has originally a private Dominion, exclusive of the rest of Mankind, in any of [its fruits],…yet being given for the use of Men, there must of necessity be a means to appropriate them some way or other before they can be of any use, or at all beneficial to any particular Man.’ Locke, V, §26, 3—12: 328. All references to Locke are to this edition of his Second Treatise.Google Scholar
  3. 9.
    John Hodgson, ‘To Treat or Not to Treat: That Is the Question for Serum’, Bio/Technology, 13 (1995): 333. Of 1300 US biotech companies in 1995, 800 were biopharmaceuticals; Europe had about 100 biopharmaceutical companies.CrossRefGoogle Scholar
  4. Mike Ward, ‘European biotech is gaining momentum’, Bio/Technology, 13 (1995): 311.CrossRefGoogle Scholar
  5. 10.
    See, for example, T. Adler, ‘Debating BST ’til the cows come home’, Science News, 149, 4 (1996): 52–3.CrossRefGoogle Scholar
  6. 11.
    Mike Ward, ‘European food rules creep forward’, Bio/Technology, 13 (1995): 1428–9.CrossRefGoogle Scholar
  7. 12.
    More practical political reasons might have been a factor. See Mike Ward, ‘EU agrees on patents but nixes BST for 5 years’, Bio/Technology, 13 (1995): 212. The suffering of animals used for human benefit and profit is not a new issue and is certainly not unique to rDNA techniques.CrossRefGoogle Scholar
  8. See, for example, Rebecca Dresser, ‘Ethical and Legal Issues in Patenting New Animal Life’, Jurimetrics Journal, 28, 4 (Summer 1988): 422–4. However, it is reasonable to suggest that rDNA opens a new stage in human manipulation that raises new questions.Google Scholar
  9. 13.
    Public opinion surveys in the US, Europe and Japan show very clear differences in people’s risk perception depending upon the application. RDNA is deemed safer when applied to microbes than to animals or food products or humans. Bernhard Zechendorf, ‘What the Public Thinks About Biotechnology’, Bio/Technology, 12 (1994): 873–5. Research related to germ-line genetic changes is highly controversial, even among those involved in rDNA research. Concerns include disruptions in cell development and growth, and a slippery slope toward eugenics, fuelled (some fear) by an alliance between genetic engineers and big business.CrossRefGoogle Scholar
  10. Jeffrey L. Fox, ‘The ethical roar of germ-line gene therapy’, Bio/Technology, 13 (1995): 18–19.CrossRefGoogle Scholar
  11. 14.
    Rick Walter, ‘We must boost public acceptance of biotech’, Bio/Technology, 13 (1995): 216–17;CrossRefGoogle Scholar
  12. Bernard Dixon, ‘Biotech consumers discriminate’, Bio/Technology, 13 (1995): 20.CrossRefGoogle Scholar
  13. 15.
    James Thompson, ‘Rogue Workers and Change Agents’, Government Executive, 28, 4 (1996): 49.Google Scholar
  14. 16.
    Margaret Mellon and Jane Rissler, ‘Transgenic Crops: USDA Data on Small-Scale Tests Contribute Little to Commercial Risk Assessment’, Bio/Technology, 13 (1995): 96.CrossRefGoogle Scholar
  15. 17.
    Tim Beardsley, ‘Advantage: Nature’, Scientific American, 274, 5 (1996): 33. Beardsley notes that genes for pest-resistance might spread to weeds and give them a reproductive advantage.CrossRefGoogle Scholar
  16. 18.
    John Kinsman, ‘Farmer’s Rights: What is Fair?’ in June Fessenden MacDonald (ed.), Genes for the Future: Discovery, Ownership, Access (Ithaca, NY: National Agricultural Biotechnology Council, 1995): 106–7.Google Scholar
  17. 19.
    According to Stephen Edington, Germany has initiated a series of steps to promote biotechnology and become a significant force in this field. Edington, ‘Germany: A Dominant Force by the Year 2000?’, Bio/Technology, 13 (1995): 752–6.CrossRefGoogle Scholar
  18. 21.
    US liberalism consigns the care of the very qualities it requires to function well — the fostering of values, of principles of the common good — to the private realm. Walter Berns, ‘Privacy, Liberalism and the Role of Government’, in Robert L. Cunningham (ed.), Liberty and the Rule of Law (College Station: Texas A&M University Press, 1979): 210.Google Scholar
  19. 27.
    In 1978, there were 30 patent applications for biotechnology; in 1992, there were over 11 000. Jean B. Fordis and Lawrence M. Sung, ‘How to Avoid Patent Rejection’, Bio/Technology, 13 (1995): 42.CrossRefGoogle Scholar
  20. 28.
    J. Travis, ‘Pig cells used for Parkinson’s disease’, Science News, 148, 40 (1995): 230. There is a large number of works available on the ethical issues surrounding fetal tissue use; see, for example, ‘Ethics of Fetal Tissue Transplantation’, Western Journal of Medicine, 159, 3 (September 1993): 400–7.CrossRefGoogle Scholar
  21. 29.
    Russ Hoyle, ‘Biotech is still searching for a bioethics forum’, Bio/Technology, 13 (1995): 736.Google Scholar
  22. 32.
    Charles J. Beck and Thomas H. Ulrich, ‘Environmental release permits’, Bio/Technology, 11 (1993): 1524–8. Advocates of biotechnology emphasize that rDNA pesticides will be less toxic and therefore environmentally preferable.CrossRefGoogle Scholar
  23. See, for example, Russ Hoyle, ‘Pesticide policy is Clinton’s acid test’, Bio/Technology, 11 (1993): 1105–6.CrossRefGoogle Scholar
  24. 33.
    Utilitarianism does rely on the principle of general welfare, but its intense support of the legitimacy of preferences and hostility to moral rights cannot provide a basis for public policy, particularly at the margins of knowledge. David Lyons, ‘Utility and Rights’, in J. Roland Pennock and John W. Chapman (eds), Ethics, Economics and the Law, Nomos XXIV (NY: New York University Press, 1982): 107–38, argues the hostility of utilitarianism to moral rights.Google Scholar
  25. 34.
    Langdon Winner has recently commented on a ‘know-nothing policy’ that abandons any attempt by government to seek the public good, denying that there is an identifiable public good which could serve to guide public policy for technological development. All guidance comes from the private sector, which is to say, the market place. Langdon Winner, ‘Know-Nothing Technology Policy’, Technology Review, 99, 2 (February/March 1996): 55.Google Scholar
  26. 35.
    Carroll E. Neeseman and James E. Hough, ‘The Infringement Exemption’, Bio/Technology, 13 (1995): 1065–6.CrossRefGoogle Scholar
  27. 38.
    Moore v. Regents, University of California, 51 Cal. 3d 120, 793 P.2d 479 (1990) cited in Michael A. Gollin, ‘Biological Materials Transfer Agreements’, Bio/Technology, 13 (1995): 243. Gollin notes that the Thirteenth Amendment of the US Constitution, in abolishing slavery, made property rights in the human body problematic.CrossRefGoogle Scholar

Copyright information

© Palgrave Macmillan, a division of Macmillan Publishers Limited 1997

Authors and Affiliations

  • Odelia Funke

There are no affiliations available

Personalised recommendations